Abstract PS3-10-14: Survival Outcome in Premenopausal ER+/PR+ HER2− Breast Cancer Stratified by Nodal Status: a National Cancer Database (NCDB) Experience

Clinical Cancer Research 2026

View at publisher
Authors: Lan Lei, A. Marra, Madison T. Canning, J. M. Switchenko, Shipra Gandhi
DOI: 10.1158/1557-3265.sabcs25-ps3-10-14
Cited by: 0

Abstract

Abstract Background: The comparative benefit of chemotherapy (CT) versus endocrine therapy (ET) in premenopausal women with stage I-III estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and HER2-negative (HER2-) breast cancer (BC) remains unclear. This study examined differences in survival outcomes among patients with node-negative (N0) and node-positive (N1) disease stratified by treatment modality. Methods: We analyzed data from NCDB for women

Fields of Study & Subjects

Breast Cancer Treatment Studies Endometrial and Cervical Cancer Treatments Breast Lesions and Carcinomas

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PS3–10
Publication date
17 February 2026
Language
EN